{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T11:22:41Z","timestamp":1775474561408,"version":"3.50.1"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,21]]},"DOI":"10.7759\/cureus.21478","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T18:07:38Z","timestamp":1642788458000},"source":"Crossref","is-referenced-by-count":3,"title":["Calciphylaxis Cutis Associated With Fibroblast Growth Factor Receptor (FGFR) Inhibitor Therapy: A New Challenge"],"prefix":"10.7759","author":[{"given":"Paige","family":"Griffith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslaw","family":"Jedrych","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Sunshine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel A","family":"Laheru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Yarchoan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13552","article-title":"Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines","volume":"26","author":"Lacouture ME","year":"2021","unstructured":"Lacouture ME, Sibaud V, Anadkat MJ, Kaffenberger B, Leventhal J, Guindon K, Abou-Alfa G. Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines. Oncologist. 2021, 26:316-26. 10.1002\/onco.13552","journal-title":"Oncologist"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa GK","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, et al.. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020, 21:671-84. 10.1016\/S1470-2045(20)30109-1","journal-title":"Lancet Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.3_suppl.265","article-title":"Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement","volume":"39","author":"Javle MM","year":"2021","unstructured":"Javle MM, Roychowdhury S, Kelley RK, et al.. Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement. J Clin Oncol. 2021, 39:265. 10.1200\/JCO.2021.39.3_suppl.265","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"24","author":"Loriot Y","year":"2019","unstructured":"Loriot Y, Necchi A, Park SH, et al.. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019, 24:338-48. 10.1056\/NEJMoa1817323","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.11.022","article-title":"Calciphylaxis associated with the fibroblast growth factor receptor inhibitor erdafitinib","volume":"7","author":"Macklis P","year":"2021","unstructured":"Macklis P, Chung C, Kaffenberger B. Calciphylaxis associated with the fibroblast growth factor receptor inhibitor erdafitinib. JAAD Case Rep. 2021, 7:125. 10.1016\/j.jdcr.2020.11.022","journal-title":"JAAD Case Rep"},{"key":"ref6","article-title":"Fibroblast growth factor receptor inhibitors and nonuremic calciphylaxis","volume":"157","author":"Hirner J","year":"2020","unstructured":"Hirner J, Cleary JM, Sheets A, Murphy G, LeBoeuf N. Fibroblast growth factor receptor inhibitors and nonuremic calciphylaxis. JAMA Dermatol. 2020, 157:119-21.","journal-title":"JAMA Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/cup.13319","article-title":"Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor","volume":"45","author":"Arudra K","year":"2018","unstructured":"Arudra K, Patel R, Tetzlaff MT, et al.. Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. J Cutan Pathol. 2018, 45:786-90. 10.1111\/cup.13319","journal-title":"J Cutan Pathol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505292","article-title":"Calciphylaxis","volume":"378","author":"Nigwekar SU","year":"2018","unstructured":"Nigwekar SU, Thadhani R, Brandenburg VM. Calciphylaxis. N Engl J Med. 2018, 378:1704-14. 10.1056\/NEJMra1505292","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Guti\u00e9rrez OM","year":"2008","unstructured":"Guti\u00e9rrez OM, Mannstadt M, Isakova T, et al.. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008, 359:584-92. 10.1056\/NEJMoa0706130","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/78720-calciphylaxis-cutis-associated-with-fibroblast-growth-factor-receptor-fgfr-inhibitor-therapy-a-new-challenge","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:43:23Z","timestamp":1707507803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/78720-calciphylaxis-cutis-associated-with-fibroblast-growth-factor-receptor-fgfr-inhibitor-therapy-a-new-challenge"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.21478","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,21]]}}}